Last reviewed · How we verify
Mesalazine with hydrocortisone sodium succinate
Mesalazine with hydrocortisone sodium succinate is a Small molecule drug developed by Xijing Hospital of Digestive Diseases. It is currently FDA-approved.
At a glance
| Generic name | Mesalazine with hydrocortisone sodium succinate |
|---|---|
| Sponsor | Xijing Hospital of Digestive Diseases |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mesalazine with hydrocortisone sodium succinate CI brief — competitive landscape report
- Mesalazine with hydrocortisone sodium succinate updates RSS · CI watch RSS
- Xijing Hospital of Digestive Diseases portfolio CI
Frequently asked questions about Mesalazine with hydrocortisone sodium succinate
What is Mesalazine with hydrocortisone sodium succinate?
Mesalazine with hydrocortisone sodium succinate is a Small molecule drug developed by Xijing Hospital of Digestive Diseases.
Who makes Mesalazine with hydrocortisone sodium succinate?
Mesalazine with hydrocortisone sodium succinate is developed and marketed by Xijing Hospital of Digestive Diseases (see full Xijing Hospital of Digestive Diseases pipeline at /company/xijing-hospital-of-digestive-diseases).
What development phase is Mesalazine with hydrocortisone sodium succinate in?
Mesalazine with hydrocortisone sodium succinate is FDA-approved (marketed).